ISSN: 2320-2831

International Journal of Pharmacy and Analytical Research (IJPAR)

IJPAR |Vol.14 | Issue 3 | Jul - Sept -2025

www.ijpar.com

DOI : https://doi.org/10.61096/ijpar.v14.iss3.2025.811-819

Research

Determination of NK1 and 5-HT3 Antagonists using a Validated RP-HPLC Method

Shiva Kumar Tejavath[1], Perli. Kranti Kumar[*2], Yadagiri Phalguna[3], N. Sriram[4]

[1]Assistant Professor, Department of Pharmaceutical Analysis, Sri Dattha Institute of Pharmacy, Hyderabad, Telangana.
[2]Professor, Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra.*
[3]Associate Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra
[4]Professor, Holy Mary Institute of Technology and Science, College of Pharmacy, Bogaram, Keesara, Hyderabad, India.

Author for Correspondence: Dr. Perli. Kranti Kumar, M. Pharm; Ph.D.
Email: drpkk1987@gmail.com

Published on: 23 Sep 2025

Published by:
Futuristic Publications

Abstract

New strategy was laid out for concurrent assessment of Netupitant and Palonosetron by RP-HPLC method. The chromatographic circumstances were effectively created for the detachment of Netupitant and Palonosetron by utilizing Inertsil C18 (4.6mm ×250mm, 5µm molecule size), stream rate was 1.0 ml/min, portable stage proportion was (55:45% v/v) Methanol: Phosphate cushion pH 4.8 (pH was changed with ortho phosphoricacid), location frequency was 282nm. The instrument utilized was WATERS Partnership 2695 detachment module, Programming: Engage 2, 996 PDA locator. The maintenance times were viewed as 1.688mins and 3.282mins. The % virtue of Netupitant and Palonosetron was viewed as 99.86%. The framework reasonableness boundaries for Netupitant and Palonosetron, for example, hypothetical plates and following variable were viewed as 7586, 1.69 and 6235 and 1.58, the goal was viewed as 10.85. The insightful strategy was approved by ICH rules (ICH, Q2 (R1)). The linearity investigation of Netupitant and Palonosetron was found in focus scope of 100µg-500µg and 30µg-70µg and relationship coefficient (r2) was viewed as 0.999 and 0.999, % recuperation was viewed as 100.112% and 100.16%, %RSD for repeatability was 0.1702 and 0.043 separately. The accuracy study was exact, vigorous, and repeatable. The LOD esteem was viewed as 2.1µg/ml and 1.28µg/ml, and LOQ esteem was 6.3µg/ml and 3.84µg/ml for Netupitant and Palonosetron individually. The consequences of study showed that the proposed RP-HPLC strategy is a basic, exact, exact, tough, strong, quick and reproducible, which might be helpful for the standard assessment of Netupitant and Palonosetron in drug measurement structure.

Keywords: Netupitant, Palonosetron, RP-HPLC, Simultaneous estimation.

INTRODUCTION

Palonosetron (Hotel, business trademark Aloxi) is a 5-HT3 bad guy utilized in the counteraction and treatment of chemotherapy-prompted sickness and retching (CINV). It is the best of the 5-HT3 bad guys in controlling deferred CINV sickness and spewing that show up over 24 hours after the principal portion of a course of chemotherapy and is the main medication of its group endorsed for this utilization by the U.S. Food and Medication Organization. Starting around 2008, it is the latest 5-HT3 adversary to enter clinical use.1-3 IUPAC name (5S)- 3-[(3S)- 1-azabicyclo [2.2.2] octan-3- yl]-3-azatricyclo [7.3.1.0^{5}, ^{13}] trideca-1(12),9(13),10-trien-2-one. Sub-atomic weight is 296.4. Sub- atomic equation is C19H24N2O. Palanosetron was viewed as is effectively solvent in water, dissolvable in propylene glycol, and marginally solvent in ethanol and isopropyl liquor, Dissolvable in Methanol.



Figure 1: Structure of Palanosetron

Netupitant is an antiemitic drug endorsed by the FDA in October 2014 for use in mix with palonosetron for the counteraction of intense and deferred spewing and queasiness related with malignant growth chemotherapy including exceptionally emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor bad guy. The blend drug is advertised by Eisai Inc. what's more, Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.4-6 IUPAC name 2-[3,5- bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl) pyridin-3-yl] propenamide. Sub-atomic weight is 578.603g/mole. Sub-atomic recipe is C30H32F6N4O. Netupitant was viewed as Solvent in DMSO. It is marginally dissolvable in water and openly solvent in a scope of natural solvents like CH3)2CO, toluene, and methanol, dissolvable in isopropanol.



Figure 2: Structure of Netupitant

The writing overview uncovered that There are not many techniques revealed in that frame of mind for examination of Netupitant and Palonosetron alone or in blend with different medications in the unadulterated structure and drugs definitions by HPLC.[7-11] Considering the requirement for a reasonable, financially savvy RP-HPLC strategy for routine investigation of Synchronous assessment of Netupitant and Palonosetron in Programming interface and Drug dose structure, endeavors were made to foster basic, exact, precise and practical scientific strategy for the assessment of Tamsulosin and Dutasteride. The proposed technique will be approved according to ICH rules. The target of the proposed work is to foster a new, basic, delicate, exact and conservative scientific technique and approval for the Synchronous assessment of Netupitant and Palonosetron in Programming interface and Drug measurements structure by utilizing RP-HPLC. To approve the created technique as per ICH rules for the planned logical application i.e., to apply the proposed strategy for examination of the medication in its dose structure. To apply the created technique for the concurrent assessment of Netupitant and Palonosetron in Programming interface and Drug measurement structure.

MATERIALS AND METHODS

Synthetics and Reagents: Netupitant and Palanosetron were gotten as a gift test from sura preparing lab, Hyderabad. NaH2PO4 was insightful grade provided by Finerchem restricted, Orthophosphoric corrosive (Merck), and Water and Methanol for HPLC (Lichrosolv (Merck).

Equipment and Chromatographic Conditions: The chromatography was performed on a Waters 2695 HPLC framework, outfitted with an auto sampler, UV indicator and Engage 2 programming. Examination was done at 282 nm with section Phosphate Support (pH-4.8): Methanol (55:45% v/v), aspects at 350C temperature. The improved portable stage comprises of. Stream rate was kept up with at 1 ml/min and run time for 6 min.

Preparation of solutions
Readiness of versatile stage: Precisely estimated 500 ml (half) of HPLC Methanol and 350 ml of Acetonitrile (35%) and 150 ml of Water (15%) were blended and degassed in a computerized ultrasonicater for 10 minutes and afterward sifted through 0.45 µ channel under vacuum channel.

Diluent Preparation
Precisely estimated 450 ml (45%) of HPLC Methanol and 550 ml of Phosphate Support (55%) were blended and degassed in a computerized ultra sonicater for 15 minutes and afterward sifted through 0.45 µ channel under vacuum channel.

Preparation of the Netupitant and Palanosetron standard solution
Preparation of standard solution: (Netupitant)
Precisely gauge and move 10 mg of Netupitant, working norm into a 10ml of clean dry volumetric carafes add around 7ml of diluent and sonicate to break up and evacuation of air totally and make volume sufficient with the diluent.

Preparation of standard solution
(Palanosetron)Precisely gauge and move 10 mg of Palanosetron working norm into a 10ml of clean dry volumetric jars add around 7ml of diluent and sonicate to disintegrate and expulsion of air totally and make volume sufficient with the diluent. Further pipette 3ml of Netupitant, 0.5ml of Palanosetron from stock arrangements in to a 10ml volumetric jar and weaken sufficient with diluent.

Procedure
Infuse the examples by changing the chromatographic circumstances and record the chromatograms, note the states of appropriate pinnacle elution for performing approval boundaries according to ICH rules.

Preparation of Sample Solution
Take normal load of Tablet and squash in a mortar by utilizing pestle and weight 10 mg identical load of Netupitant, Palanosetron test into a 10ml clean dry volumetric carafe and add around 7ml of Diluent and sonicate to disintegrate it totally and make volume sufficient with a similar dissolvable. **Procedure:**
Further pipette 1.2ml of Netupitant, Palanosetron from above stock arrangement into a 10ml volumetric jar and weaken sufficient with diluent.

METHOD

The created chromatographic technique was approved for framework appropriateness, linearity exactness, accuracy, roughness and power according to ICH rules.

Framework reasonableness boundaries: To assess framework reasonableness boundaries, for example, maintenance time, following element and USP hypothetical plate count, the portable stage was permitted to course through the section at a stream pace of 1.0 ml/min for 6 minutes to equilibrate the segment at encompassing temperature. Chromatographic division was accomplished portable period of piece Phosphate Support (pH-4.8): Methanol (55:45% v/v) was permitted to move through the segment at a stream pace of 1.0 ml each moment. Maintenance time, following element and USP hypothetical plate count of the created strategy are by infusing a volume of 20 L of standart into Inertsil ODS C 18 section (4.6 x 250mm, 5µm), the displayed in table 1.

Assay of pharmaceutical formulation: The proposed approved technique was effectively applied to decide Netupitant and Palanosetron in their drug measurement structure. The outcome got for Netupitant and Palanosetron was equivalent with the relating named sums and they were displayed in Table-2.

RESULTS AND DISCUSSION



Figure 3: Standard chromatogram



Figure 4: Sample chromatogram



Figure 5: Blank chromatogram

Table 1: System suitability parameters

Parameters	Netupitant	Palanosetron
Retention time	1.688	3.282
USP Plate count	7586	6235
USP Tailing	1.69	1.58

Table 2: Assay results for Netupitant

	Label Claim (mg)	% Assay
Netupitant	80	99.86
	20	99.86

Linearity: The linearity study was performed for the convergence of 100ppm to 500ppm and30 ppm to 70 ppm level. Each level was infused into chromatographic framework. The region of each level was utilized for computation of relationship coefficient. Infuse each level into the chromatographic framework and measure the pinnacle region. Plot a chart of pinnacle region versus focus (on X-hub fixation and on Y-pivot Pinnacle region) and work out the connection coefficient. The resulte are displayed in table 3.

Table 3: Linearity results for Netupitant and Palanosetron

Netupitant		Palanosetron	
Concentration(µg/ml)	**Area**	**Concentration(µg/ml)**	**Area**
100	585985	30	268764
200	1182468	40	356958
300	1768785	50	445631
400	2326852	60	535186
500	2856874	70	624698
Correlation coefficient	0.999	Correlation coefficient	0.999



Figure 4: Linearity graph for Netupitant



Figure 5: Linearity graph for Palanosetron

Accuracy studies: The not entirely settled by help of recuperation study. The recuperation technique did at three level half, 100 percent, 150%. Infuse the standard arrangements into chromatographic framework. Work out the Sum found and Sum added and ascertain the singular recuperation and mean recuperation values. The outcomes are displayed in table 4,5.

Table 4: Showing accuracy results for Netupitant

%Concentration (at specification Level)	Average Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	879537	150	150.048	100.032	
100%	1743252	300	300.521	100.172	
150%	2609693	450	450.598	100.132	100.112%

Table 5: Showing accuracy results for Palanosetron

%Concentration (at specification Level)	verage Area	mount Added (ppm)	mount Found (ppm)	% Recovery	Mean Recovery
50%	224271	25	25.114	100.456%	
100%	445748.3	50	49.952	99.904%	
150%	670006.3	75	75.101	100.134%	100.16%

Precision Studies: accuracy was caliculated from Coefficient of difference for six duplicate infusions of the norm. The standard arrangement was infused for multiple times and estimated the region for each of the six Infusions in HPLC. The %RSD for the area of six imitate infusions was found. The resulte are displayed in table 6.

Table 6: Precision results for Netupitant and Palanosetron

S. No	Netupitant	palanosetron
1	1658254	426598
2	1658952	426589
3	1654857	426985
4	1659854	426587
5	1653298	426515
Mean	**1657043**	**426654.8**
Std.dev	**2820.29**	**187.5692**
%RSD	**0.1702**	**0.043963**

Ruggedness: To assess the middle accuracy of the technique, Accuracy was performed on various day. The standard arrangement was infused for multiple times and estimated the region for each of the five infusions in HPLC. The %RSD for the area of five repeat infusions was found. The resulte are displayed in table 7 and 8.

Table 7: Intermediate precision resultes for Netupitant and Palanosetron on day 1

S. No	Sample Area 1	Sample Area 2
1	1665985	436598
2	1662598	436855
3	1668484	436598
4	1664598	436587
5	1663579	436741
6	1664587	432659
Mean	**1664972**	**436006.3**
Std. Dev.	**2060.327**	**1643.285**
% RSD	**0.123745**	**0.376895**

Table 8: Intermediate precision resultes for Netupitant and Palanosetron on day 2:

Injection	Area for Netupitant	Area for Palanosetron
Injection-1	1648598	415985
Injection-2	1642587	415267
Injection-3	1649852	415986
Injection-4	1648754	415265
Injection-5	1645289	415874
Injection-6	1647581	415632
Average	1647110	415668.2
STD Deviation	2699.291	337.2106
%RSD	0.16388	0.081125

Robustness: As a component of the Vigor, conscious change in the Stream rate, Portable Stage organization, Temperature Variety was had to assess the effect on the technique. The stream rate was changed at 0.9 ml/min to 1.1ml/min. The Frequency changed from 243nm to 247nm. The resulte are displayed in table 9,10,11,12

Robustness results for Netupitant

Table 9: Organic Composition results for Netupitant

Flow Rate (ml/min)		System suitability Results		
		USP Plate Count	USP Tailing	Retention Time (min)
Less Flow rate	0.8	7365	1.62	1.868
Actual Flow rate	1	7586	1.69	1.688
More Flow rate	1.2	7254	1.61	1.544

Table 10: Wavelength variation results for Netupitant:

Flow Rate (ml/min)		System suitability Results		
		USP Plate Count	USP Tailing	Retention Time (min)
Less Flow rate	0.8	6284	1.51	3.621
Actual Flow rate	1	6235	1.58	3.282
More Flow rate	1.2	6168	1.56	2.998

Robustness results for Palanosetron

Table 11: Flow variation results for Palanosetron

Flow Rate (ml/min)		System suitability Results		
		USP Plate Count	USP Tailing	Retention Time (min)
Less Flow rate	0.8	6284	1.51	3.621
Actual Flow rate	1	6235	1.58	3.282
More Flow rate	1.2	6168	1.56	2.998

Table 12: Organic Composition results for Palanosetron

Organic phase		System suitability Results		
		USP Plate Count	USP Tailing	Retention Time (min)
Less organic phase	50:50	6182	1.54	3.621
Actual organic phase	55:45	6235	1.58	3.282
More organic phase	60:40	6322	1.56	2.302

LOD and LOQ: The awareness of RP not set in stone from LOD and LOQ. Which were determined from the adjustment bend involving the accompanying conditions according to ICH rules. The resulte are displayed in table 13.

LOD = 3.3σ/S and LOQ = 10 σ/S, where

σ= Standard deviation of y intercept of regression line, S = Slope of the calibration curve

Table 13: LOD, LOQ of Netupitant and Palanosetron

Drug	LOD	LOQ
Netupitant	2.10	6.30
Palanosetron	1.28	3.84

CONCLUSION

The proposed HPLC strategy was viewed as straightforward, exact, precise and delicate for the concurrent assessment of Netupitant and Palanosetron in drug measurement structures. Consequently, this strategy can without much of a stretch and helpfully take on for routine quality control examination of Netupitant and Palanosetron in unadulterated and its drug measurement structures.

REFERENCES

1. De Leon A: Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting. Proc (Bayl Univ Med Cent). 2006 Oct;19(4):413-6.
2. Stoltz R, Cyong JC, Shah A, Parisi S: Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004 May;44(5):520-31.
3. Rubenstein EB: Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004 May;2(5):284-9.
4. Darmani NA, Zhong W, Chebolu S, Mercadante F: Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation. Pharmacol Biochem Behav. 2015 Apr;131:104-11. doi: 10.1016/j.pbb.2015.02.010. Epub 2015 Feb 14. [Article]
5. Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W: Effect of netupitant, a highly selective NK(1) receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87. doi: 10.1007/s00520-013-1857-9. Epub 2013 Jun 11
6. Lanzarotti C, Rossi G: Effect of netupitant, a highly selective NK(1) receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer. 2013 Oct;21(10):2783-91. doi: 10.1007/s00520-013-1855-y. Epub 2013 Jun 1.
7. Narayudu Yandamuri, Development and Validation of RP-HPLC Method for Simultaneous Estimation of Netupitant and Palonosetron in Pharmaceutical Dosage Form, Research gate, February 2019.
8. P.Sri haritha, Dr. S. Shobha Rani, Dr. M. Ajitha, K. Rambabu, Stability indicating method development and validation for the simultaneous estimation of palonosetron and netupitant by RP-HPLC in its bulk form, journal of pharma research, November 2017.
9. NVMS Bhagavnji**,** PVV Satyanarayana,Karanam Sekhar, D. Naniprasad Development and Combined Tablet Dosage Form, International Journal of Pharmaceutical Sciences Review and Research, 41(1), November -December 2016; Article No. 17*,* Pages: 81-87.
10. Dr. Gampa Vijay Kumar1*, B. Sravanthi2, N. Gayathri Aparna3, Development and Validation of RP HPLC Method for Simultaneous Estimation of Netupitant and Palonosetron in Pharmaceutical Dosage Form. pharma research library2019.
11. Uttam Prasad Panigrahy1*, A. Sunil Kumar Reddy2, A novel validated RP-HPLC-DAD method for the simultaneous estimation of Netupitant and Palonosetron in bulk and pharmaceutical dosage form with forced degradation studies. International Journal of Chem Tech Research, Vol.8, No.10 pp 317-337.
12. Kumar PK, Nilewar SS, Bonthu MG, Dudhe SP, Dudhe PB. Computational Drug Design and Docking Studies of Thiazole Derivatives Targeting Bacterial DNA Gyrase. Indian Journal of Pharmaceutical Chemistry and Analytical Techniques. 2025 Aug 7:40-53.
13. Bandaru N, Noor SM, Kammili ML, Bonthu MG, Gayatri AP, Kumar PK. Methionine restriction for

cancer therapy: From preclinical studies to clinical trials. Cancer Pathogenesis and Therapy. 2025 Jan 6.
14. Bandaru N, Bonthu MG, Gayatri AP, Metri S, Kumar PK, Addanki A, Nallapaty S, Priya KS, Nadhreddy DT, Gowravi PN. Review on Exploring Role of Vitamin D on Alzheimer's Disease: Mechanistic Insights and Implications. Journal of Pharmacology and Pharmacotherapeutics. 2025 Jun;16(2):164-71.
15. Bandaru N, Noor SM, Kammili ML, Bonthu MG, Gayatri AP, Kumar PK. Cancer Pathogenesis and Therapy.
16. Kumar PK, Dhulipalla NL, Gadicherla V, Dasari V. International Journal of Pharmacy and Analytical Research (IJPAR).
17. Bharadwaj N, Das AB, Sunil R, Devi S, Kumar PK, Bhadkariya S, Kakkar S, IA C. asPotentialDPP-4InhibitorsforDiabetesManagement. Journal of Neonatal Surgery. 2025;14(12s):955.
18. Rekha NV, Kumar PK, Dasari V. Quantification And Phytochemical Examination Of Acacia Catechu Willd By HPTLC. Journal of Engineering Sciences. 2023;14(1):670-6.
19. Dudhe SP, Dudhe PB, Mundhe SM, Rojin RG, Vijukumar A, Cherian IV, Das S, Perli KK. The Digital Revolution in Education: Historical Perspectives and Future Directions. Revolutionizing Education With Remote Experimentation and Learning Analytics. 2025:489-508.
20. Behera A, Joshi V, Mohapatra R, Vishwakarma D, Sarkar S, Das S, Begum T, Kumar PK. Empagliflozin-Loaded Floating Density-Modulated Drug Delivery System as a Novel Approach for Sustained Therapy in Type 2 Diabetes Mellitus with Sodium-Glucose Co-Transporter-2 Inhibition. Cuestiones de Fisioterapia. 2025 Feb 19;54(3):4357-68.
21. Madhuri VD, Aparna TN, Dasari V, Kumar PK. A prospective of primary and novel approaches to the colon targeted drug delivery system.
22. Dhulipalla NL, Gadicherla V, Dasari V, Kumar PK. International Journal of Pharmacology and Clinical Research (IJPCR).
23. Uplanchiwar VP, Sarma KN, Mujawar T, Mythily V, Kranti P. Chronotherapeutic Circadian-Based Pulsatile Drug Delivery of Etodolac for Morning Stiffness in Rheumatoid Arthritis. Journal of Neonatal Surgery. 2025;14(4s):833.
24. Bandaru N, Shamim N, Nagalakshmi SB, Sunanda T, Hanisha C, Gambhire MS. Preparation of Platinum Nanoparticles of Biophytum reinwardtii and Evaluation of Neuroprotective Activity of MPTP-induced Parkinson's Disease in Zebra Fish. Biomedical and Pharmacology Journal. 2024 Sep 30;17(3):1635-45.
25. Krantikumar P, Godasu SK, Raju P, Vuyyala G, Dasari V. A study on method development and validation of drugs used in hospital acquired bacterial pneumonia. J Eng Sci. 2022;12:278-90.